The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026 [0.03%]
KRAS靶向治疗在转移性胰腺癌中的革命:来自RASolute-302里程碑式试验和2026年美国临床肿瘤学会(ASCO)会议上新兴的等位基因特异性策略的见解
Serena Pillozzi,Elisa Giommoni,Giulia Petroni et al.
Serena Pillozzi et al.
Survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) has long been limited by a dismal second-line therapeutic ceiling dictated by conventional chemotherapy. However, breakthrough data from the ASCO 2026 Annual Meeting and the pu...
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data [0.03%]
PD-1抗体联合化疗治疗HER2阴性晚期胃或胃食管交界癌的临床疗效:RATIONALE-305研究的事后分析及患者层面合并数据分析
Ming-Yu Lai,Hao-Xiang Wu,Ming-Ming He et al.
Ming-Yu Lai et al.
While multiple phase III trials have established the survival benefit of adding a programmed cell death protein 1 (PD-1) antibody to first-line chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced ...
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment [0.03%]
成人前体B细胞急性淋巴细胞白血病中CD20的表达动力学及其对利妥昔单抗治疗的影响
Monika Szczepanowski,Johanna Richter,Sonja Bendig et al.
Monika Szczepanowski et al.
Background: Baseline CD20 expression ≥ 20% in B-cell acute lymphoblastic leukemia (B-ALL) has been associated with poorer outcomes, which improved after rituximab introduction into frontline therapy for CD20-positive cas...
Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities [0.03%]
铜稳态和铜依赖性细胞死亡重塑肿瘤微环境:机制、免疫调节及治疗机会
Guoqing Li,Wenlong Wang
Guoqing Li
Copper, an essential trace element with dual functions in cancer progression, drives tumor growth via oncogenic signaling, metabolic plasticity, and extracellular matrix remodeling. By contrast, copper overload triggers cuproptosis, a form ...
Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications [0.03%]
癌症干细胞的可塑性:机制、免疫微环境相互作用及治疗意义
Jingyu Tan,Tao Wen,Jian Liu et al.
Jingyu Tan et al.
Cancer stem cells (CSCs) represent functionally defined and phenotypically plastic tumor cell populations implicated in therapeutic resistance, relapse, and metastasis. CSC plasticity is regulated through coordinated stemness signaling and ...
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors [0.03%]
抗GDF-15抗体Visugromab联合抗PD-1抗体Nivolumab治疗抗PD-1/L1失效的实体瘤I/II期临床试验的长期随访研究
Ignacio Melero,María de Miguel,Elena Garralda Cabanas et al.
Ignacio Melero et al.
Background: Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizi...
From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine [0.03%]
从肿瘤靶向到肿瘤通达:表面工程菌作为精确诊疗活体药物的转化医学研究
Liyuan Qiao,Leyang Wu,Yihan Xiao et al.
Liyuan Qiao et al.
The concept of bacterial therapy dates back over a century to clinical observations that incidental infections could induce tumor regression. Recent advances in genetic engineering and synthetic biology have since transformed bacteria into ...
Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities [0.03%]
抗体-寡核苷酸缀合物:设计原理、细胞内递送和转化机遇
Yuqian Li,Xinlin Liu,Fuyuan Zhang et al.
Yuqian Li et al.
Antibody-oligonucleotide conjugates (AOCs) have emerged as a promising therapeutic platform that integrates the targeting capability of antibodies with the gene-regulatory potential of oligonucleotide payloads. By enabling cell or tissue se...
Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting [0.03%]
肿瘤学中新兴的人工智能进展:来自2026年AACR年度会议的最新更新
Yan-Ruide Li,Zhengyao Shao,Haochen Nan
Yan-Ruide Li
Advances presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlight a shift from standalone artificial intelligence (AI) models to integrated, agentic systems across oncology. Platforms such as Synapse en...
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment [0.03%]
针对实体瘤微环境的双模块纳米抗体CAR-T细胞技术平台
Yangzi Li,Xuan Wang,Shangkun Zhang et al.
Yangzi Li et al.
Background: CAR-T therapy is effective in hematologic cancers but faces challenges in solid tumors due to antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Systemic CTLA-4 blockade enhances immu...